Latest Research on Diabetes Type 2 Cure 2022: Key Breakthroughs

In 2022, remarkable achievements in diabetes research have emerged globally, supported by Diabetes UK. Explore the latest breakthroughs in the quest for a type 2 diabetes cure, as we reflect on the exceptional accomplishments of researchers worldwide. Stay informed on the latest research findings.

Diabetes mellitus type 1

A unique collaboration to propel the hunt for a type 1 cure
We launched a new partnership with JDRF and the Steve Morgan Foundation in April, after the Foundation’s astounding £50 million commitment.

The Type 1 Diabetes Grand Challenge is being supported by the largest single donation ever made to type 1 diabetes research in the United Kingdom. We will form scientific dream teams to work on bigger and bolder ideas in three areas that have the greatest potential to change type 1 therapies and lives.

  • Therapies to repair or replace pancreatic beta cells, which create insulin.
  • Treatments to block the immune system’s attack on the beta cells that create insulin.
  • Future insulins, such as those that respond to fluctuations in blood sugar levels.

The first Grand Challenge initiatives will begin in 2023, and the newly launched Type 1 Diabetes Grand Challenge website will keep you up to date on all the latest news.

In the United Kingdom, the first type 1 screening method was implemented.

On World Diabetes Day, we announced the launch of the UK’s first-ever trial screening effort to identify children at high risk of developing type 1 diabetes.

As part of the ELSA experiment, children will be examined for blood markers that indicate the immune system has started to prepare for an attack on the pancreas. Before a person develops symptoms and is diagnosed with type 1, the warning signs may be present for years, if not decades.

ELSA will help our researchers determine the most effective method to launch a countrywide screening strategy for type 1 diabetes in the United Kingdom. Screening may dramatically alter how we diagnose and treat type 1 diabetes.

If you have a child aged 3 to 13, learn more about how to participate.

The United States has approved the first drug to delay the onset of type 1 diabetes.

The United States approved the first immunotherapy medicine to prevent the development of type 1 diabetes in patients at high risk only a few days after we published ELSA.

Teplizumab, also known as Tzield, inhibits the immune system’s progression and promotes the survival of insulin-producing beta cells, delaying the development of type 1 diabetes.

Teplizumab’s approval in the United States corresponded precisely with the start of our ELSA investigation. Without screening measures, it would be difficult to identify and support persons at risk of type 1 diabetes who may benefit from immunotherapies.

Teplizumab is now being studied for use in the United Kingdom, and when combined with screening activities, it may herald in a new era of type 1 diabetes management.

New Flash Research

Our researchers at the University of Manchester investigated the impact of second-generation Flash (FreeStyle Libre 2) on blood sugar levels and quality of life in people with type 1 diabetes.

They observed that not only did Flash assist patients remain in range and decrease their average blood sugar levels, but it also reduced some of the everyday stress associated with type 1 diabetes.

The findings highlight the importance of making this technology accessible to everyone who may benefit from it.

AI aids in the early detection of type 1 diabetes.

Dr. Julia Townson and her colleagues used our funding to develop a prediction tool that might uncover tendencies that could suggest cases of undiscovered type 1 diabetes in children. They accomplished this by combining artificial intelligence and electronic health data from over one million children.

They observed that the tool was efficient in identifying 75% of children who will develop type 1 diabetes in the following 90 days, which might help them obtain a diagnosis and start getting life-saving insulin sooner.

It’s a fantastic step that might open the way for GPs to use this technology more often in the future. This might make it simpler for more children to get an early diagnosis of type 1 diabetes and obtain the best possible start in life.

Diabetes mellitus type 2

It has also been a particularly busy year in the realm of type 2 diabetes research.

The genes involved in fat storage are being decoded.

Researchers from the Universities of Exeter and Brunel revealed a strong relationship between type 2 diabetes and the genes that determine where our body fat is stored earlier this year.

The researchers examined data from over 500,000 people and determined that certain people had genes that allow them to store extra fat everywhere, including the liver, pancreas, and subcutaneously. This is linked to an increased risk of illnesses such as type 2 diabetes. While some individuals are genetically predisposed to have less liver fat and more skin fat, which reduces their risk of acquiring illnesses such as type 2 diabetes.

This study is a promising step towards better understanding the biology of type 2 diabetes and why people with comparable body weights may have such disparities in their risk of developing the condition.

More people may be eligible for tax relief.

ReTUNE is a ground-breaking study of type 2 diabetes remission in people with reduced body weights. Diabetes UK funded it, and new data was provided early last year.

70% of those who lost weight on a low-calorie diet went into remission.

The findings indicated for the first time how a comprehensive low-calorie diet regimen may help people with type 2 diabetes and lower body weights go into remission. And that the treatment is to remove harmful fat from the pancreas and liver.

This study might provide many more people the chance to put their type 2 diabetes into remission.

A Healing NewDAWN

We collaborated with the NIHR this year to assist NewDAWN, a £2.2 million programme that will raise the possibility that more people will achieve remission.

The project’s purpose is to create an entirely new, statewide NHS support service for patients who have just been diagnosed with type 2 diabetes and are overweight or obese. To offer everyone the best chance of remission, the programme will allow patients to try out several weight loss strategies until they find one that works for them.

Insomnia has been linked to type 2 diabetes.

Our researchers at the University of Bristol announced earlier this year, with cooperation from the universities of Manchester, Exeter, and Harvard, that treating insomnia may help prevent or cure type 2 diabetes by reducing blood sugar levels.

Researchers examined 337,000 people’s sleep habits and blood sugar levels and found that individuals who struggled to get or stay asleep on a regular basis had higher blood sugar levels than those who did not.

Although these findings help us understand how sleep disturbances may impact the development of type 2 diabetes, further study is needed before these findings may lead to novel techniques for controlling or treating the illness.

New drugs to treat and prevent type 2 diabetes will be available shortly.

This year, the United States approved a brand new class of drugs known as GLP-1 receptor agonists to help people with type 2 diabetes regulate their blood sugar levels.

The medications work by replicating the hormones that tell our bodies to make insulin and our brains to stop eating.

In 2022, we also heard promising results from clinical research suggesting that these medications also assisted obese people in losing weight. The medications have not yet been approved for the treatment of obesity. However, since being fat or overweight increases the risk of acquiring type 2 diabetes, more research may result in the development of innovative and more effective therapies and prevention measures.

This tremendous progress was made possible by your gifts and support during 2022. Our scientists simply could not make progress without your help.

Leave a Comment

Scroll to Top